Peptide Therapeutics Market by Technology, API Type, Drug Class, Application, End User

Description

List of Tables

The Global Peptide Therapeutics Market is forecasted to grow significantly, with a projected USD 33.40 billion in 2023 at a CAGR of 11.03% and expected to reach a staggering USD 69.56 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Peptide Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Peptide Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Hybrid Phase, Liquid Phase, and Solid Phase. The Solid Phase is projected to witness significant market share during forecast period.

Based on API Type, market is studied across CMO and In-house. The In-house is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Calcitonins, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin. The Vasopressin is projected to witness significant market share during forecast period.

Based on Application, market is studied across Anti-infective, Cancer, Cardio Vascular Disease Respiratory, Central Nervous System, Dermatology, Gastrointestinal, Metabolic, and Renal. The Central Nervous System is projected to witness significant market share during forecast period.

Based on End User, market is studied across Hospitals, Pharmaceutical Industries, and Research Laboratories. The Research Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 36.39% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Peptide Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Peptide Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Peptide Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peptide Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Peptide Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Peptide Therapeutics Market?

6. What is the market share of the leading vendors in the Global Peptide Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Peptide Therapeutics Market?

Product Code: MRR-030EE4851584

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Peptide Therapeutics Market, by Technology, 2022 vs 2030
4.3. Peptide Therapeutics Market, by API Type, 2022 vs 2030
4.4. Peptide Therapeutics Market, by Drug Class, 2022 vs 2030
4.5. Peptide Therapeutics Market, by Application, 2022 vs 2030
4.6. Peptide Therapeutics Market, by End User, 2022 vs 2030
4.7. Peptide Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of cancer, cardiovascular disorders (CVDs) and metabolic disorder
  - 5.1.1.2. Technology advancement and R & D investment in new peptides
- 5.1.2. Restraints
  - 5.1.2.1. Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides
- 5.1.3. Opportunities
  - 5.1.3.1. Presence of strong product pipeline portfolio
  - 5.1.3.2. Adoption of new platforms that develop next-generation protein or peptide therapeutics
- 5.1.4. Challenges
  - 5.1.4.1. Presence of stringent safety regulations
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Peptide Therapeutics Market, by Technology

6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase

7. Peptide Therapeutics Market, by API Type

7.1. Introduction
7.2. CMO
7.3. In-house

8. Peptide Therapeutics Market, by Drug Class

8.1. Introduction
8.2. Calcitonins
8.3. Glucagon & Analogs
8.4. Insulins
8.5. Luteinizing Hormone-Releasing Hormone
8.6. Somatostatins
8.7. Vasopressin

9. Peptide Therapeutics Market, by Application

9.1. Introduction
9.2. Anti-infective
9.3. Cancer
9.4. Cardio Vascular Disease Respiratory
9.5. Central Nervous System
9.6. Dermatology
9.7. Gastrointestinal
9.8. Metabolic
9.9. Renal

10. Peptide Therapeutics Market, by End User

10.1. Introduction
10.2. Hospitals
10.3. Pharmaceutical Industries
10.4. Research Laboratories

11. Americas Peptide Therapeutics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Peptide Therapeutics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Peptide Therapeutics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing